EN DE
Watch Neuronetics Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Neuronetics Inc (STIM) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Neuronetics Inc stock $1.76, price $1.28, upside +37.5%, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US64131A1051

NI Neuronetics Inc logo Thin data Nov 11, 2026

Neuronetics Inc

STIM · US

Cheap enough by our rule, but weak company and price moving sideways: meets 1 of 3 rules.

Follow free in the weekly email
Even on cautious assumptions the value is 3% above the price ($1.32). 
Fair value $1.76 · Fairly valued 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +24.8 %/yr in USD) 
Quality 32/100 
Loss-making · -14.5% net margin (TTM) 
High debt 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 9/100 · thin data
Thin data 
Estimate
Watch Neuronetics Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.87 $0.6100 Fair Value $1.76 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.6100 – $7.87 · fair‑value band $1.32 – $2.20 · the $1.28 price screens below the $1.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Neuronetics in your weekly email

Every Wednesday you see whether Neuronetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

Show moreShow less

The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology.

The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Stock analysis

Neuronetics Inc (STIM) currently trades at $1.28, while our estimate is $1.76, so the stock looks roughly fairly valued today (gap 27.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.32 (bear) to $2.20 (bull), the price of $1.28 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Neuronetics Inc reported revenue of $149M in FY2025 versus $55.3M in FY2021, a compound +28.1%/yr. Reported net income was −$39.0M in FY2025.

Key figures

Market cap $169M Micro · P/S ratio 1.06 · EPS (TTM) $−0.3200 · Net margin −14.5% · Return on equity −85.6% · Return on assets (EBIT) −24.5% (5-year average) · Operating margin 1.3% · Revenue (TTM) $160M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 38%, STIM screens cheaper than that median.

Fair Value

Bear $1.32 Fair Value $1.76 Bull $2.20
Price $1.28 · Upside +37.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 77
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 23
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 18
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • SaleJorey Chernett10% owner3,335,411 shares at $1.34$4.5MNov 13, 2026
  • BuyJorey Chernett10% owner13× since Mar 17, 2026: 3,675,314 shares, avg. $1.34$4.9MNov 9, 2026
  • SaleSteven PfanstielFormer EVP, CFO and Treasurer8,569 shares at $1.34$11,482Mar 19, 2026
  • SaleWilliam Andrew MacanEVP, CLO and CS5× since Feb 10, 2026: 37,646 shares, avg. $1.48$55,589Mar 19, 2026
  • SaleKeith J SullivanFormer Officer & Director4× since Feb 10, 2026: 129,564 shares, avg. $1.49$192,798Mar 19, 2026

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 17, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+99.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.8%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−45.3% (2020) → −21.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch STIM, get fair value alerts →

Compare Neuronetics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside +37.5% · Top 25%
Profitability
Return on assets −27.6% · Bottom 25%
Net margin (12 months) −14.5% · Below median
Operating margin (12 months) 1.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 12.5% · Above median
Balance sheet
Debt / equity 3.30× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 7.57× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 1.06× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)83 · sector 19
FUTURE (revenue growth)63 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Boston Scientific Corporation BSX $43.03 $48.77 +13% vs STIM
DexCom, Inc DXCM $82.04 $91.66 +12% vs STIM
Stryker Corporation SYK $317.54 $340.60 +7% vs STIM
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥185.38 ¥197.34 +6% vs STIM
GE HealthCare Technologies Inc GEHC $81.84 $69.92 −15% vs STIM
Siemens Healthineers AG SHL €43.30 €34.51 −20% vs STIM
Edwards Lifesciences Corporation EW $105.43 $81.94 −22% vs STIM
Medtronic plc MDT $102.32 $74.89 −27% vs STIM
Abbott Laboratories, ABT $104.71 $75.28 −28% vs STIM
Koninklijke Philips N.V PHIA €27.16 €15.23 −44% vs STIM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neuronetics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Neuronetics Inc Fair Value". https://www.fairvalue-calculator.com/stock/STIM

Frequently asked questions

Is Neuronetics Inc (STIM) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $1.76 versus a price of $1.28, about +38% upside (fairly valued).
What is the fair value of STIM?
Our estimate for Neuronetics Inc is $1.76 (as of Nov 11, 2026), built from audited fundamentals. The current price: $1.28.
What is the quality score of STIM?
Neuronetics Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuronetics Inc (STIM)?
Our calculated price target is the estimate of $1.76 (as of Nov 11, 2026). Cautious scenario $1.32, optimistic scenario $2.20. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Neuronetics Inc stock forecast for 2026?
Our estimate puts fair value at $1.76, about +38% upside versus a price of $1.28 (fairly valued). Cautious scenario $1.32, optimistic scenario $2.20. The calculation is refreshed regularly with new filings.
What is the revenue of Neuronetics Inc (STIM)?
Neuronetics Inc reported trailing-twelve-month revenue of about $160M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Neuronetics Inc (STIM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuronetics Inc it is $1.76 per share (as of Nov 11, 2026), against a price of $1.28.
Is Neuronetics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, STIM trades below its calculated fair value: price $1.28, fair value $1.76, a gap of about +38% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STIM?
No. The price is what the market pays today ($1.28); the fair value is what the company's own numbers justify ($1.76). For Neuronetics Inc the two are $0.4800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuronetics Inc worth?
The market values Neuronetics Inc at about $169M (market capitalisation, as of Nov 11, 2026). Per share that is $1.28; our models calculate a fair value of $1.76 per share.
What do the bullish and bearish scenarios say about STIM?
Our models span a range for Neuronetics Inc: cautious scenario $1.32, base $1.76, optimistic $2.20 per share (as of Nov 11, 2026, price $1.28). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neuronetics Inc (STIM)?
Balance-sheet figures for Neuronetics Inc (as of Nov 11, 2026): return on equity −85.6%, debt of 3.30 per unit of equity (balance sheet 30 Sep 2026). They feed the Quality Score of 32/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is STIM from its 52-week high?
Neuronetics Inc trades at $1.28, about 61% below its 52-week high of $3.30 and 8% above the low of $1.18 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of $1.76 is for.
Which stocks are comparable to Neuronetics Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuronetics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $1.28, calculated fair value $1.76 (+38%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. Neuronetics Inc currently trades 27% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuronetics Inc (STIM)?
The closing price on Nov 17, 2026 was $1.28. Our estimate is $1.76, about +38% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuronetics Inc right now?
The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($1.32). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Neuronetics Inc

How large is the market capitalisation of Neuronetics Inc (STIM)?
The market capitalisation of Neuronetics Inc is $169M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuronetics Inc (STIM)?
The price-to-sales ratio of Neuronetics Inc is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuronetics Inc (STIM)?
Earnings per share at Neuronetics Inc are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neuronetics Inc (STIM)?
The net margin of Neuronetics Inc is −14.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neuronetics Inc (STIM)?
The return on equity (ROE) of Neuronetics Inc is −85.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuronetics Inc (STIM)?
On an EBIT basis the return on assets of Neuronetics Inc is −24.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuronetics Inc (STIM)?
The operating margin of Neuronetics Inc is 1.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neuronetics Inc (STIM)?
Revenue at Neuronetics Inc is growing 12.5% versus a year earlier (3y avg +31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Neuronetics Inc (STIM) generate?
The free cash flow of Neuronetics Inc is −$21.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Neuronetics Inc (STIM) carry?
The net debt of Neuronetics Inc is $65.6M (balance sheet 30 Sep 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Neuronetics Inc in the live analysis

One click puts Neuronetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.